07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

PerkinElmer sales and marketing update

PerkinElmer launched its PreeclampsiaScreen T1 serum test in the U.S. to identify asymptomatic patients in the first trimester of pregnancy who are at high risk for developing early onset preeclampsia. The blood test measures three...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Clinical News

CPAPP-A* test: Pivotal trial data

Beckman Coulter Inc. reported data from an analysis of 3,782 patients with non-ST-segment-elevation myocardial infarction (NSTEMI) ACS in the double-blind, placebo-controlled, international Phase III MERLIN-TIMI 36 trial of Ranexa ranolazine to treat ACS showing that...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Company News

Beckman Coulter, Dade Behring deal

The companies cross-licensed rights to a collection of cardiac biomarkers. DADE granted BEC rights to use a combination of placental growth factor (PlGF) , soluble vascular endothelial growth factor (VEGF) receptor 1 (FLT1) , soluble...